Background: Pancreatic adenocarcinoma remains one of the worst digestive cancers. Surgical resection is the main target when treating a patient with curative intent. Aim: To assess angiolymphatic invasion as a prognostic factor in resected pN0 pancreatic cancer. Methods: Thirty-eight patients were submitted to pancreatoduodenectomy due to head pancreatic cancer. Tumor size, margins, lymph nodes, pTNM staging, angiolymphatic and perineural invasion were described in the pathologists' reports. Results: Most patients were female. Overall median survival was 13 months. Gemcitabine was the regimen of choice for chemotherapy in selected patients; however, it did not improve overall survival. pR0 resection had better survival compared with pR1. Within the pN0 group, survival was significantly better in patients without angiolymphatic invasion. Conclusion: Angiolymphatic invasion in N0 pancreatoduodenectomy can be demonstrated by the Hematoxylin-Eosin stain and may predict a poor prognosis factor for those patients.
Background: Pancreatic adenocarcinoma remains one of the worst digestive cancers. Surgical resection is the main target when treating a patient with curative intent. Aim: To assess angiolymphatic invasion as a prognostic factor in resected pN0 pancreatic cancer. Methods: Thirty-eight patients were submitted to pancreatoduodenectomy due to head pancreatic cancer. Tumor size, margins, lymph nodes, pTNM staging, angiolymphatic and perineural invasion were described in the pathologists' reports. Results: Most patients were female. Overall median survival was 13 months. Gemcitabine was the regimen of choice for chemotherapy in selected patients; however, it did not improve overall survival. pR0 resection had better survival compared with pR1. Within the pN0 group, survival was significantly better in patients without angiolymphatic invasion. Conclusion: Angiolymphatic invasion in N0 pancreatoduodenectomy can be demonstrated by the Hematoxylin-Eosin stain and may predict a poor prognosis factor for those patients.
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: Gloria M Petersen; Mariza de Andrade; Michael Goggins; Ralph H Hruban; Melissa Bondy; Jeannette F Korczak; Steven Gallinger; Henry T Lynch; Sapna Syngal; Kari G Rabe; Daniela Seminara; Alison P Klein Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-04 Impact factor: 4.254
Authors: C Max Schmidt; Emilie S Powell; Constantin T Yiannoutsos; Thomas J Howard; Eric A Wiebke; Chad A Wiesenauer; Joel A Baumgardner; Oscar W Cummings; Lewis E Jacobson; Thomas A Broadie; David F Canal; Robert J Goulet; Eardie A Curie; Higinia Cardenes; John M Watkins; Patrick J Loehrer; Keith D Lillemoe; James A Madura Journal: Arch Surg Date: 2004-07
Authors: James Helm; Barbara A Centeno; Domenico Coppola; Marcovalerio Melis; Mark Lloyd; Jong Y Park; Dung-Tsa Chen; Mokenge P Malafa Journal: Cancer Date: 2009-09-15 Impact factor: 6.860